A chemistry-focused CRO/CDMO supporting drug discovery, process development, analytical development, CMC and API manufacturing from discovery through commercial stages.
Core modalities
Pre-generated AI ranking
Score model: gpt-5.4-miniGenerated: Aug 24, 2026, 7:34 PM PDTRead-only snapshot
Sutro has strong internal ADC technology, but external linker, payload or specialist chemistry could still be complementary.
Recommended services
Public evidence
Official site describes multiple next-generation single- and dual-payload ADC programs. Source
IDEAYA combines small molecules and ADCs, overlapping with several CDMO 1 chemistry offerings.
Recommended services
Public evidence
Official pipeline lists targeted small molecules and ADC programs across clinical stages. Source
Nurix degrader and degrader-antibody conjugate programs overlap with CDMO 1 degrader, linker and chemistry services.
Recommended services
Public evidence
Official pipeline identifies targeted degraders and degrader-antibody conjugates. Source
Arvinas has ongoing PROTAC programs that fit CDMO 1 degrader chemistry and later-stage process services.
Recommended services
Public evidence
Official pipeline includes clinical PROTAC programs in neurology and oncology. Source
Kymera targeted protein degraders align directly with CDMO 1 PROTAC and complex chemistry capabilities.
Recommended services
Public evidence
Official site describes a clinical targeted protein degradation pipeline. Source
Monte Rosa molecular glue programs require specialized medicinal chemistry, analog synthesis and process development aligned with CDMO 1 capabilities.
Recommended services
Public evidence
Official pipeline shows molecular glue degraders in clinical and preclinical stages. Source
Treeline operates multiple inhibitor, degrader and ADC programs, creating broad overlap with CDMO 1 drug-discovery chemistry services.
Recommended services
Public evidence
Official medicines page lists Phase 1 small-molecule and degrader programs plus broader ADC work. Source
PepGen peptide-oligonucleotide conjugates partially overlap with CDMO 1 peptide capabilities, but oligonucleotide manufacturing is not a core stated strength.
Recommended services
Public evidence
Official pipeline centers on peptide-conjugated oligonucleotides. Source
Wave is primarily an RNA-medicines company, leaving only limited adjacent chemistry fit for CDMO 1.
Recommended services
Public evidence
Official site describes RNA editing, RNAi, splicing and antisense programs. Source
Dyne conjugated oligonucleotide programs offer some chemistry overlap but are outside CDMO 1 main advertised modality focus.
Recommended services
Public evidence
Official pipeline centers on oligonucleotide-antibody fragment conjugates. Source
Revolution Medicines has multiple complex RAS inhibitor programs, offering technical fit, though its maturity may reduce reliance on a new external vendor.
Recommended services
Public evidence
Official pipeline lists several clinical and IND-enabling oral RAS inhibitors. Source
Relay has a broad precision small-molecule pipeline and may benefit from flexible synthesis and process capacity as programs advance.
Recommended services
Public evidence
Official pipeline describes clinical and discovery-stage precision small molecules. Source
Arrowhead is primarily focused on RNAi, so direct fit with CDMO 1 core small-molecule CRO/CDMO services is limited.
Recommended services
Public evidence
Official pipeline is dominated by RNAi medicines. Source
Frontier has a multi-program covalent small-molecule pipeline spanning clinical and preclinical work, closely matching CDMO 1 chemistry and scale-up capabilities.
Recommended services
Public evidence
Official pipeline shows clinical and preclinical covalent small-molecule programs. Source
Nimbus runs a renewable small-molecule pipeline against difficult targets where external chemistry and process capacity could complement internal design.
Recommended services
Public evidence
Official site lists clinical and preclinical small-molecule programs in oncology, immunology and metabolism. Source
Septerna is advancing several oral small-molecule GPCR programs from discovery into the clinic, fitting CDMO 1 discovery-to-CMC services.
Recommended services
Public evidence
Official pipeline lists multiple discovery, IND-enabling and Phase 1 oral small-molecule programs. Source
Neumora is advancing several small-molecule programs through preclinical and clinical transitions where chemistry and CMC support may be relevant.
Recommended services
Public evidence
Official pipeline lists small-molecule programs from preclinical through Phase 2. Source
Kura small-molecule programs fit process and API capabilities, but commercial-stage maturity may mean established vendor relationships.
Recommended services
Public evidence
Official pipeline includes an approved product and additional clinical small molecules. Source
Odyssey has several small-molecule immunology programs across Phase 2, IND-enabling and discovery stages.
Recommended services
Public evidence
Official pipeline lists multiple oral small-molecule inflammatory-disease programs. Source
Immunome has several ADC programs where CDMO 1 linker, payload and custom chemistry could be relevant.
Recommended services
Public evidence
Official pipeline lists a clinical ADC and multiple preclinical ADCs. Source
